BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma

Antengene Announces NDA Submission for XPOVIO® in Indonesia

"In just six months, we have submitted NDAs for XPOVIO® in three ASEAN countries, Malaysia, Thailand and Indonesia, supporting...

May 17, 2023 | News

Cytiva and Pall Life Sciences merge to form a comprehensive solutions provider for biotechnology challenges, with focus on innovation and digitalization

Discover how the combined technical expertise, talent, and portfolio offerings of these two distinguished brands are driving the next generation of medicin...

May 12, 2023 | News

Ascletis approved for Phase IIa clinical trial of ASC10 for RSV infection in China

--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Do...

May 09, 2023 | News

Bliss Biopharmaceutical Collaborates with Eisai for Clinical Trial of BB-1701 with Strategic Option

This collaboration with Eisai is an important advancement in BlissBio's corporate development plan to further develop BB-1701 globally and help advance BB-...

May 08, 2023 | News

EirGenix's Breast Cancer Biosimilar EG1206A Meets Phase 1 Trial Goals

Comparing EG1206A to Roche's Perjeta® US and EU, results of the clinical data analysis show that the main test indicators have met the pharmacokinetics...

May 08, 2023 | News

Formosa Pharmaceuticals and AimMax Therapeutics Submit NDA to US FDA for APP13007 for Post-Operative Pain and Inflammation after Ocular Surgery.

This proprietary homogeneous nanosuspension has a solution-like appearance which offers great comfort to the eyes and enhanced drug penetration into ocular...

May 05, 2023 | News

Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

-Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances A...

May 01, 2023 | News

ALX Oncology collaborates with Sanofi to evaluate Evorpacept with SARCLISA for multiple myeloma

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 ...

April 28, 2023 | News

Bridgewest Perth Pharma to commercialize Sterile Injectable drugs under LumaCina business unit

The newly created business leverages the acclaimed team and production facility recently acquired by Bridgewest Group from Pfizer (Perth) Pty Ltd, a subsid...

April 26, 2023 | News

I-Mab Doses First Patient in Phase 3 Study of Lemzoparlimab for MDS in China

The Phase 3 trial is a randomized, controlled, open-label, multi-center study to evaluate the efficacy and safety of lemzoparlimab in combination with AZA ...

April 25, 2023 | News

Ascentage Pharma Achieves EU GMP Compliance with Zero Deficiencies

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-...

April 25, 2023 | News

Everest Medicines Launches First-in-Disease Therapy for IgA Nephropathy in China's Hainan Boao Pilot Zone.

The launch of this early-access program in Hainan marks the beginning of a new treatment era for IgA nephropathy in China, where Everest can...

April 24, 2023 | News

Bridge Biotherapeutics Receives FDA Approval for First-in-Human Study of BBT-207, a 4th Gen EGFR TKI.

The company has been notified by the FDA that the Phase 1/2 clinical trial may proceed The latest preclinical data explored the antitumor effica...

April 24, 2023 | News

Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA

The FDA has extended the Prescription Drug User Fee Act (PDUFA) action date by three months to July 24, 2023 to allow additional time to review requested u...

April 21, 2023 | News

Stay Connected